--- title: "Enanta Pharmaceuticals, Inc. (ENTA.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ENTA.US.md" symbol: "ENTA.US" name: "Enanta Pharmaceuticals, Inc." industry: "Biotechnology" datetime: "2026-05-20T02:58:44.076Z" locales: - [en](https://longbridge.com/en/quote/ENTA.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ENTA.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ENTA.US.md) --- # Enanta Pharmaceuticals, Inc. (ENTA.US) ## Company Overview Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.enanta.com](https://www.enanta.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:12.000Z **Overall: D (0.62)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 244 / 386 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 7.37% | | | Net Profit YoY | 35.71% | | | P/B Ratio | 3.35 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 391104211.00 | | | Revenue | 69213000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -59.00% | E | | Profit Margin | -89.56% | E | | Gross Margin | 100.00% | A | | Revenue YoY | 7.37% | C | | Net Profit YoY | 35.71% | B | | Total Assets YoY | -2.57% | D | | Net Assets YoY | 24.64% | A | | Cash Flow Margin | 12.65% | D | | OCF YoY | 7.37% | C | | Turnover | 0.22 | D | | Gearing Ratio | 62.95% | D | ```chart-data:radar { "title": "Longbridge Financial Score - Enanta Pharmaceuticals, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "7.37%", "rating": "" }, { "name": "Net Profit YoY", "value": "35.71%", "rating": "" }, { "name": "P/B Ratio", "value": "3.35", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "391104211.00", "rating": "" }, { "name": "Revenue", "value": "69213000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-59.00%", "rating": "E" }, { "name": "Profit Margin", "value": "-89.56%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "7.37%", "rating": "C" }, { "name": "Net Profit YoY", "value": "35.71%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-2.57%", "rating": "D" }, { "name": "Net Assets YoY", "value": "24.64%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "12.65%", "rating": "D" }, { "name": "OCF YoY", "value": "7.37%", "rating": "C" }, { "name": "Turnover", "value": "0.22", "rating": "D" }, { "name": "Gearing Ratio", "value": "62.95%", "rating": "D" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -6.46 | 405/386 | - | - | - | | PB | 3.43 | 276/386 | 5.64 | 3.16 | 1.77 | | PS (TTM) | 5.78 | 121/386 | 6.09 | 5.31 | 2.51 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-19T04:00:00.000Z Total Analysts: **6** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 5 | 83% | | Overweight | 1 | 17% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 13.76 | | Highest Target | 28.00 | | Lowest Target | 12.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ENTA.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ENTA.US/norm.md) - [Related News](https://longbridge.com/en/quote/ENTA.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ENTA.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**